Leiden, the Netherlands, 15 March 2013 - OctoPlus N.V. ("OctoPlus" or the
"Company") (Euronext: OCTO), announces that, following the acquisition of 98.6%
of all issued and outstanding ordinary shares in the Company (the "Shares") by
Reddy Netherlands B.V., a fully-owned subsidiary of Dr. Reddy's Laboratories
Ltd., delisting of the Shares was approved by NYSE Euronext Amsterdam. The
delisting of the Shares will take effect on 16 April 2013. The last trading day
will be 15 April 2013.
The Company is reminding shareholders that following delisting shareholders will
no longer be able to trade the Shares via the NYSE Euronext Amsterdam stock
exchange in the usual way. Furthermore, it remains uncertain if, to what extent,
under which conditions and at what cost processing of the Shares in the
Euroclear giro system may be continued after delisting.
This is a press release by OctoPlus N.V. pursuant to the provision of Article
5:25i of the Dutch Act on the Financial Supervision (Wet op het financieel
toezicht).
About OctoPlus
OctoPlus is a leading European provider of advanced drug formulation and
clinical scale manufacturing services to the pharmaceutical and biotechnology
industries, with a focus on difficult to formulate active pharmaceutical
ingredients. OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the
symbol OCTO. For more information about OctoPlus, please visit our website
www.octoplus.nl.
In addition, OctoPlus is a specialty pharmaceutical company focused on the
development and manufacture of improved injectable pharmaceuticals based on our
proprietary drug delivery technologies that exhibit fewer side effects, improved
patient convenience and a better efficacy/safety balance than existing
therapies. OctoPlus also focuses on the development of long-acting, controlled
release versions of known protein therapeutics, peptides and small molecules,
including specialty generics.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
Click here for the press release in PDF:
http://hugin.info/137076/R/1685731/552396.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
[HUG#1685731]
